metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Performance of 2 automated real time PCR methods for the detection of Bordetella...
Journal Information
Vol. 41. Issue 10.
Pages 640-641 (December 2023)
Vol. 41. Issue 10.
Pages 640-641 (December 2023)
Scientific letter
Full text access
Performance of 2 automated real time PCR methods for the detection of Bordetella pertussis and Bordetella parapertussis
Rendimiento de 2 técnicas de PCR en tiempo real para la detección de Bordetella pertussis y Bordetella parapertussis
Visits
327
Marta Pérez-Abeledoa, Verónica Barrioluengob, Elena Maesob, Juan Carlos Sanza,c,
Corresponding author
juan.sanz@salud.madrid.org

Corresponding author.
a Unidad de Microbiología Clínica, Laboratorio Regional de Salud Pública de la Comunidad de Madrid, Dirección General de Salud Pública de la Comunidad de Madrid, Madrid, Spain
b DiaSorin Iberia S.A., Madrid, Spain
c CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Distribution of RealCycler® BORD-T and Simplexa™ Bordetella Direct results in terms of the total number of samples of suspected pertussis studied.
Full Text

The aetiological agent of pertussis is B. pertussis, but B. parapertussis and B. holmesii can cause very similar clinical manifestations.1B. bronchiseptica infection is rare, clinically distinct and affects debilitated patients.2 The most commonly used targets for the diagnosis of Bordetella spp. by PCR have been the IS481 and IS1001 sequences. IS481 is present in B. pertussis and B. holmesii, and may also be present in B. bronchiseptica. IS1001 is found in B. parapertussis and occasionally in B. bronchiseptica.3–5 One way to distinguish species is based on the use of specific primers for the promoter region of the pertussis toxin gene (ptxA-pr), which is specific to B. pertussis.3,5,6 An alternative is the B. pertussis porin gene (BPTD_0837).4 The BP283 gene has also been used to identify B. pertussis.7 Numerous kits are now available for the molecular diagnosis of pertussis. However, their interpretation can be complex due to the possibility of detecting the same sequences in different species. The aim of this study was to evaluate the performance of two real-time PCR methods, RealCycler® BORD-T (Progenie Molecular), and Simplexa™ Bordetella Direct, (DiaSorin Molecular LLC) for the diagnosis of pertussis.

Fifty nasopharyngeal swab/nasopharyngeal wash samples obtained from patients with clinical suspicion of pertussis between July 2018 and January 2020 were studied, and 44 nasopharyngeal swab samples received in February 2022 for diagnosis of SARS-CoV-2 by RT-PCR were studied as a control group. Samples were kept frozen at −80°C until studied. All samples were from epidemiological surveillance studies and were processed simultaneously with the RealCycler® BORD-T assay after nucleic acid extraction and Simplexa™ Bordetella Direct assay directly from the sample without prior extraction. The results of the two techniques were interpreted according to the manufacturers' respective recommendations.

For the 50 suspected pertussis samples, the results with RealCycler® BORD-T were: 28 (56%) B. pertussis, 12 (24%) Bordetella spp., six (12%) B. parapertussis or B. bronchiseptica, three (6%) co-infection with different Bordetella spp. and one (2%) negative. With Simplexa™ Bordetella Direct, the results were: 39 (78%) B. pertussis, six (12%) B. parapertussis, two (4%) co-infection by different Bordetella spp., two (4%) negative and one (2%) invalid due to amplification inhibition (Table 1). In 47 samples with suspicion of pertussis (94%), the two methods matched regarding the identification at the genus level or co-infection with Bordetella spp. In 27 (54%) of these cases the two techniques identified the species as B. pertussis. In 11 cases (22%) where Simplexa™ Bordetella Direct classified the result as B. pertussis, RealCycler® BORD-T classified it as Bordetella spp. In the six cases (12%) identified as B. parapertussis by Simplexa™ Bordetella Direct, the RealCycler® BORD-T result was either B. parapertussis or B. bronchiseptica. All 44 samples collected for SARS-CoV-2 detection were negative for Bordetella spp. in both techniques.

Table 1.

Distribution of RealCycler® BORD-T and Simplexa™ Bordetella Direct results in terms of the total number of samples of suspected pertussis studied.

RealCycler® BORD-TSimplexa™ Bordetella DirectTotal
  IS481  IS1001  BP283    IS481  IS1001 
B. pertussis  Positive  Negative  Positive  B. pertussis  Positivea  Negativea  27  54 
Bordetella spp.  Positive  Negative  Negative  B. pertussis  Positivea  Negativea  11  22 
B. parapertussis or B. bronchiseptica  Negative  Positive  Negative  B. parapertussis  Negativeb  Positiveb  12 
[1,0]Co-infection by different Bordetella spp.Positive  Positive  Positive  [1,0]B. pertussis and B. parapertussisPositiveb  Positiveb 
Positive  Positive  Negative  Positiveb  Positiveb   
Co-infection by different Bordetella spp.  Positive  Positive  Positive  B. pertussis  Positive  Negative 
Bordetella spp.  Positive  Negative  Negative  Negative  Negative  Negative 
Negative  Negative  Negative  Negative  Negative  Negative  Negative 
B. pertussis  Positive  Negative  Positive  Invalidc  Invalid  Invalid 
              50  100 

The results in this table are only applicable when the internal quality specifications of each of the techniques evaluated (e.g., amplification of internal controls and/or Ct within range) are met.

a

This combination of results from Simplexa™ Bordetella Direct would not rule out infection by B. holmesii.

b

This combination of results from Simplexa™ Bordetella Direct would not rule out infection by B. bronchiseptica.

c

Invalid due to amplification inhibition.

The RealCycler® BORD-T assay kit detects both IS481 and the BP283 region. This combination incorporates high sensitivity and high specificity for pertussis diagnosis. This kit also includes IS1001 to detect B. parapertussis.

Simplexa™ Bordetella includes IS481 for the detection of B. pertussis and IS1001 for B. parapertussis.8 Although the combination of positivity and negativity for each of these targets does not definitively exclude others such as B. holmesii or B. bronchiseptica, for practical purposes, in samples with clinical suspicion of pertussis the result could be considered "probable infection by" B. pertussis or B. parapertussis, as appropriate.3 This kit has shown very good sensitivity and specificity9 and excellent overall percent agreement values.10

In this study the number of samples studied is small. Furthermore, there was no "gold standard" to assess the sensitivity of the techniques, no control strains were available and discordant cases were not confirmed with a third alternative technique. However, the results of the two techniques matched well for the detection of Bordetella spp. Each technique offers its own advantages: RealCycler® BORD-T would theoretically be highly specific for B. pertussis, while Simplexa™ Bordetella Direct does not require nucleic acid extraction, making it a simple and rapid alternative.

Conflicts of interest

In this study the Simplexa™ Bordetella Direct (DiaSorin Molecular LLC) reagents were provided by DiaSorin Iberia S.A. Authors V.B. and E.M. are employees of DiaSorin Iberia S.A.

This study has been partially submitted and accepted as a submission to the XXVI National Congress of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica [Spanish Society of Infectious Diseases and Clinical Microbiology].

References
[1]
A.L. Leber.
Pertussis: relevant species and diagnostic update.
Clin Lab Med, 34 (2014), pp. 237-255
[2]
M. Ducours, P. Rispal, M.P. Danjean, Y. Imbert, E. Dupont, E.M. Traissac, et al.
Bordetella bronchiseptica infection.
Med Mal Infect, 47 (2017), pp. 453-458
[3]
European Centre for Disease Prevention and Control. Guidance and protocol for the use of realtime PCR in laboratory diagnosis of human infection with Bordetella pertussis or Bordetella parapertussis. Stockholm: ECDC; 2012. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Guidance-protocol-PCR-laboratory-diagnosis-bordatella-pertussis-parapertussis.pdf.
[4]
J.C. Sanz, R. Abad, C. Sanz, A. Miguel.
Differential diagnosis by RT-PCR of Bordetella bronchiseptica in a child without previous pathologic antecedents suffering whooping cough.
Enferm Infecc Microbiol Clin, 37 (2019), pp. 679-680
[5]
A. Valero-Rello, D. Henares, L. Acosta, M. Jane, I. Jordan, P. Godoy, et al.
Validation and implementation of a diagnostic algorithm for DNA detection of Bordetella pertussis, B. parapertussis, and B. holmesii in a pediatric referral hospital in Barcelona, Spain.
J Clin Microbiol, 57 (2019), pp. e01231-18
[6]
A. Mir-Cros, G. Codina, M.T. Martín-Gómez, A. Fàbrega, X. Martínez, M. Jané, et al.
Emergence of Bordetella holmesii as a causative agent of whooping cough, Barcelona, Spain.
Emerg Infect Dis, 23 (2017), pp. 1856-1859
[7]
W.S. Probert, J. Ely, K. Schrader, J. Atwell, A. Nossoff, S. Kwan.
Identification and evaluation of new target sequences for specific detection of Bordetella pertussis by real-time PCR.
J Clin Microbiol, 46 (2008), pp. 3228-3231
[8]
D.C. Dominguez.
A profile of the Simplexa™ Bordetella Direct assay for the detection and differentiation of Bordetella pertussis and Bordetella parapertussis in nasopharyngeal swabs.
Expert Rev Mol Diagn., 20 (2020), pp. 889-894
[9]
P. Lanotte, C. Plouzeau, C. Burucoa, C. Grélaud, S. Guillot, N. Guiso, et al.
Evaluation of four commercial real-time PCR assays for detection of Bordetella spp. in nasopharyngeal aspirates.
J Clin Microbiol, 49 (2011), pp. 3943-3946
[10]
S.K. Chow, S. Arbefeville, B.L. Boyanton Jr, E.M. Dault, J. Dunn, P. Ferrieri, et al.
Multicenter performance evaluation of the simplexa bordetella direct kit in nasopharyngeal swab specimens.
J Clin Microbiol, 59 (2020), pp. e01041-20
Copyright © 2023. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.eimce.2024.05.013
No mostrar más